This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-gene-therapy-is-entering-human-trials-could-it-protect-vision-without-lowering-eye-pressure
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Glaucoma Gene Therapy Is Entering Human Trials — Could It Protect Vision Without Lowering Eye Pressure?
For more than a century, glaucoma treatment has focused on one central strategy: lower the pressure inside the eye. Pressure-lowering eye drops, laser treatment, and surgery can slow damage, but they do not directly make retinal ganglion cells more resistant to injury. Some patients continue to lose vision even when their eye pressure appears to be well controlled.
ASP2767, an experimental gene therapy from Astellas, is designed around a different idea: deliver protective genes directly to retinal ganglion cells so that the cells may better survive glaucoma-related stress.
The treatment is now entering its first human study, registered as NCT07770685, a combined Phase 1 and Phase 2 trial. The trial is important because it is specifically designed to test a neuroprotective treatment for progressive open-angle glaucoma, not simply another pressure-lowering drug. ()
The most likely interpretation of the available evidence is that ASP2767 is intended primarily to preserve surviving retinal ganglion cells and their function. It is not yet demonstrated to regenerate a damaged optic nerve, replace dead neurons, or restore established visual-field loss.
The Bottom Line
ASP2767 is an investigational intravitreal gene therapy.
The first human trial plans to enroll approximately 156 adults with progressive open-angle glaucoma.
The public trial record does not disclose the clinical vector, gene sequence, dose levels, or names of the anti-inflammatory preventive treatments.
The strongest scientific trail connects ASP2767 to work from Quethera, a company acquired by Astellas in 2018.
The best-matching preclinical program uses an adeno-associated virus type 2 vector to express both:
Tropomyosin receptor kinase B, a receptor that supports retinal ganglion-cell survival.
Mature brain-derived neurotrophic factor, a protein that activates that receptor.
In mice and rats, the related construct preserved retinal ganglion cells and electrical measures of retinal ganglion-cell function after optic-nerve injury or experimentally elevated eye pressure.
There is no public evidence yet that the treatment regenerates long-distance optic-nerve axons or restores permanent visual-field loss.
If it works, ASP2767 would most likely be an add-on treatment used together with eye-pressure control, not a replacement for it.
---
What Is ASP2767?
Established facts
ASP2767 is:
Developed by Astellas Pharma.
Intended for optic neuropathy caused by glaucoma.
Administered by a single intravitreal injection into one eye.
Being tested in adults with progressive open-angle glaucoma.
Entering humans for the first time in the registered Phase 1/Phase 2 study.
Listed in Astellas’ ophthalmology pipeline as a gene therapy for glaucoma. ()
The public-facing trial materials describe ASP2767 as a harmless-virus-based gene therapy. The delivered genes are expected to cause retinal nerve cells to produce proteins intended to protect them and slow further vision loss. ()
What has not been officially disclosed
The publicly available clinical-trial listing does not identify:
The exact adeno-associated virus type or engineered capsid used clinically.
The promoter controlling gene expression.
The exact genes or protein sequences in the clinical product.
The vector dose levels.
The number of patients in each Phase 1 dose cohort.
The precise primary and secondary endpoint definitions.
The identity and schedule of “Prophylactic Regimen A” and “Prophylactic Regimen B.”
The clinical trial sites.
Those omissions are normal for a newly registered first-in-human gene-therapy study. Some details may be available in the investigator brochure, regulatory submissions, or later registry updates but are not currently visible in the public record I could verify.
---
The Strongest Reconstruction of ASP2767’s Mechanism
Strongly supported inference: a dual tropomyosin receptor kinase B and mature brain-derived neurotrophic factor therapy
The most important clue is the history of Quethera, a British gene-therapy company acquired by Astellas in 2018. Quethera’s glaucoma program used recombinant adeno-associated virus vectors to deliver protective genes to retinal cells. Astellas stated that the lead preclinical candidate significantly improved retinal ganglion-cell survival in experimental glaucoma models. ()
A later paper provides an unusually close match to that description. It was authored by researchers from:
The University of Cambridge.
Quethera.
Astellas.
Other institutions involved in glaucoma gene-therapy research.
The paper describes a bicistronic adeno-associated virus vector that expresses two fully humanized components:
Tropomyosin receptor kinase B, also called the TrkB receptor.
Mature brain-derived neurotrophic factor.
A short self-cleaving 2A peptide allows both proteins to be produced from a single genetic cassette. ()
The paper does not explicitly state that this published construct is identical to clinical ASP2767. Astellas may have modified the vector, promoter, capsid, protein sequences, or manufacturing process before entering human trials.
Therefore:
> Best-supported conclusion: ASP2767 is probably an optimized clinical version of the Quethera/Astellas dual tropomyosin receptor kinase B–mature brain-derived neurotrophic factor program.
> What remains unproven: the exact identity of the clinical vector and genetic cassette.
How the proposed pathway works
Brain-derived neurotrophic factor is a natural support signal used by neurons. It binds to the tropomyosin receptor kinase B receptor on retinal ganglion cells and activates intracellular survival pathways, including:
The protein kinase B pathway.
The extracellular signal-regulated kinase pathway.
Other pathways involved in cellular metabolism, synaptic maintenance, and resistance to programmed cell death.
In glaucoma, injury near the optic nerve head can interfere with the normal transport of growth and survival signals between the brain and retinal ganglion cells. The cells may then become metabolically stressed and more vulnerable to pressure, mechanical strain, reduced blood supply, oxidative stress, and inflammation.
The proposed treatment attempts to bypass part of that problem by making retinal ganglion cells produce both:
More of the survival receptor.
More of the receptor’s activating ligand.
This dual approach is scientifically important because delivering brain-derived neurotrophic factor alone can lead to reduced receptor availability over time. The related research was designed to avoid that limitation by increasing both sides of the signaling system. ()
---
Why an Intravitreal Adeno-Associated Virus Vector?
An intravitreal injection places the vector into the gel-filled cavity inside the eye. From there, the vector can contact the inner retina, including retinal ganglion cells.
Adeno-associated virus type 2 has been widely studied for retinal ganglion-cell delivery because it can transduce inner-retinal neurons after intravitreal injection. However, it is not perfectly specific. Depending on the vector design and promoter, other retinal cells may also receive the genetic material. ()
The likely advantages are:
A single injection rather than daily treatment.
Local production of the protective proteins inside the eye.
Long-lasting expression in nondividing retinal neurons.
Theoretical activity even when eye pressure is already controlled.
The likely disadvantages are:
The vector cannot be easily removed after injection.
Not every retinal ganglion cell may be transduced.
Existing antibodies against the viral capsid may reduce delivery.
Inflammation can damage the retina or optic nerve.
Excessive or poorly controlled growth-factor signaling could have unintended effects.
---
The Newly Registered Human Trial
Trial identity
The study is:
Trial number: NCT07770685.
Astellas study number: 2767-CL-0101.
Sponsor: Astellas Pharma Global Development.
Design: Phase 1, open-label, dose escalation followed by Phase 2, randomized, sham-controlled and masked.
Planned enrollment: 156 participants.
Treatment: One intravitreal injection in one study eye.
Follow-up: Approximately 52 weeks after treatment. ()
As of August 25, 2026, public registry mirrors described the study as not yet recruiting, with a planned start in August 2026 and a primary completion date in July 2030. The patient-facing listing says enrollment is expected to begin during August 2026. No trial locations were publicly posted in the record available at that time. ()
Phase 1
Phase 1 is intended to:
Test safety.
Assess tolerability.
Escalate through increasing doses.
Identify the highest dose that can be given safely.
Observe preliminary effects on visual function and retinal structure.
Phase 1 is open-label, meaning the participants and investigators know that ASP2767 is being given.
Participants in the dose-escalation portion must have relatively severe but not completely end-stage disease:
Mean deviation between −12 and −20 decibels.
Evidence of glaucomatous visual-field loss.
Corresponding optic-nerve damage.
At least one quadrant with remaining visual-field function.
